^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Microbiome modulator

    Related drugs:
    26d
    The Effects of a 6-week Pre-operative Administration of a Microbiome Modulator "WellBiome" Versus Placebo on Cardiac Surgical Outcomes and NHS Cost Savings. (clinicaltrials.gov)
    P=N/A, N=80, Recruiting, Hull University Teaching Hospitals NHS Trust | Not yet recruiting --> Recruiting
    Enrollment open • HEOR
    1m
    R-3750 ARDS: R-3750 in Patients With Late-Stage Acute Respiratory Distress Syndrome (ARDS) (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Rise Therapeutics LLC
    New P1 trial
    1m
    Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery (clinicaltrials.gov)
    P2, N=62, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Initiation date: May 2026 --> Jan 2027
    Enrollment open • Trial initiation date
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    Keytruda (pembrolizumab) • Cdactin-O (CBM588)
    1m
    ROMA LA-OPSCC2: Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2 (clinicaltrials.gov)
    P=N/A, N=30, Completed, University Health Network, Toronto | Active, not recruiting --> Completed | Trial completion date: Mar 2026 --> Sep 2025 | Trial primary completion date: Jan 2026 --> Sep 2025
    Trial completion • Trial completion date • Trial primary completion date
    2ms
    Pro-IgAN: A Study of Probiotics in IgA Nephropathy (clinicaltrials.gov)
    P=N/A, N=18, Completed, University of Leicester | Recruiting --> Completed | Trial completion date: May 2026 --> Dec 2025 | Trial primary completion date: May 2025 --> Aug 2025
    Trial completion • Trial completion date • Trial primary completion date
    2ms
    Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma. (PubMed, J Immunother Cancer)
    Early clinical data show encouraging antitumor response of CJRB-101 plus pembrolizumab in ICI-naïve metastatic NSCLC with PD-L1 >50%.
    P1 data • Journal • PD(L)-1 Biomarker • IO biomarker • First-in-human
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • CJRB-101
    2ms
    Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, City of Hope Medical Center
    New P2 trial
    |
    Cdactin-O (CBM588) • zanzalintinib (XL092)
    3ms
    COMMENCER: COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER (clinicaltrials.gov)
    P1/2, N=80, Recruiting, Massachusetts General Hospital | Trial completion date: Dec 2027 --> Aug 2028 | Trial primary completion date: Dec 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    3ms
    Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery (clinicaltrials.gov)
    P2, N=62, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: May 2027 --> Oct 2028 | Trial primary completion date: May 2027 --> Oct 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    Keytruda (pembrolizumab) • Cdactin-O (CBM588)
    3ms
    Nucleoporin TPR integrates MAPK signaling with mitogen-induced transcriptional programs. (PubMed, Cell Death Dis)
    Using a novel phospho-specific monoclonal antibody, we show that TPR is phosphorylated at Ser2155 following EGFR activation via the canonical RAS-RAF-MEK-ERK MAPK cascade, placing TPR downstream of MAPK pathway activation...Finally, immunohistochemical analysis reveals elevated TPR phosphorylation in serous ovarian carcinoma and heterogeneous phosphorylation patterns in triple-negative breast cancer, two tumor types frequently characterized by MAPK pathway hyperactivation. Together, these findings uncover a previously unappreciated role for TPR as a MAPK-responsive nuclear factor and support a model in which NPC-associated components fine-tune mitogen-induced transcriptional responses.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    3ms
    StarFish-UC: Confirmatory Clinical Study in Active Ulcerative Colitis (clinicaltrials.gov)
    P2, N=204, Recruiting, MRM Health NV | Not yet recruiting --> Recruiting
    Enrollment open
    3ms
    MPOH14: A medical research to evaluate if MaaT013 is safe and helps children and adolescent with GI-aGvHD after failed two prior therapies. (2025-524302-15-00)
    P1/2, N=6, Not yet recruiting, MaaT PHARMA
    New P1/2 trial
    |
    Jakafi (ruxolitinib) • Xervyteg (MaaT013)